Cannabinoid Receptor 2 Signaling Does Not Modulate Atherogenesis in Mice by Willecke, Florian et al.
Cannabinoid Receptor 2 Signaling Does Not Modulate
Atherogenesis in Mice
Florian Willecke
1., Katharina Zeschky
1., Alexandra Ortiz Rodriguez
1, Christian Colberg
1, Volker
Auwa ¨rter
2, Stefan Kneisel
2, Melanie Hutter
2, Andrey Lozhkin
1, Natalie Hoppe
1, Dennis Wolf
1, Constantin
von zur Mu ¨hlen
1, Martin Moser
1, Ingo Hilgendorf
1, Christoph Bode
1, Andreas Zirlik
1*
1Department of Cardiology, University of Freiburg, Freiburg, Germany, 2Forensic Toxicology, Institute of Forensic Medicine, University Medical Center Freiburg, Freiburg,
Germany
Abstract
Background: Strong evidence supports a protective role of the cannabinoid receptor 2 (CB2) in inflammation and
atherosclerosis. However, direct proof of its involvement in lesion formation is lacking. Therefore, the present study aimed
to characterize the role of the CB2 receptor in Murine atherogenesis.
Methods and Findings: Low density lipoprotein receptor-deficient (LDLR
2/2) mice subjected to intraperitoneal injections of
the selective CB2 receptor agonist JWH-133 or vehicle three times per week consumed high cholesterol diet (HCD) for 16
weeks. Surprisingly, intimal lesion size did not differ between both groups in sections of the aortic roots and arches,
suggesting that CB2 activation does not modulate atherogenesis in vivo. Plaque content of lipids, macrophages, smooth
muscle cells, T cells, and collagen were also similar between both groups. Moreover, CB2
2/2/LDLR
2/2 mice developed
lesions of similar size containing more macrophages and lipids but similar amounts of smooth muscle cells and collagen
fibers compared with CB2
+/+/LDLR
2/2 controls. While JWH-133 treatment reduced intraperitoneal macrophage
accumulation in thioglycollate-illicited peritonitis, neither genetic deficiency nor pharmacologic activation of the CB2
receptor altered inflammatory cytokine expression in vivo or inflammatory cell adhesion in the flow chamber in vitro.
Conclusion: Our study demonstrates that both activation and deletion of the CB2 receptor do not relevantly modulate
atherogenesis in mice. Our data do not challenge the multiple reports involving CB2 in other inflammatory processes.
However, in the context of atherosclerosis, CB2 does not appear to be a suitable therapeutic target for reduction of the
atherosclerotic plaque.
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Introduction
Atherosclerosis is a chronic inflammatory disease and represents
the primary cause of heart disease and stroke worldwide [1]. While
the inflammatory nature of atherosclerosis has been uncovered for
sometime already, genuine anti-inflammatory treatment options
are still lacking. Drugs with pleiotropic anti-inflammatory
properties, such as statins, are cornerstones of current state-of-
the-art therapy, while great efforts are made to find new agents
primarily designed to abate the inflammatory and immunologic
mechanisms promoting atherosclerosis and its complications. A
growing body of evidence suggests that the cannabinoid system
plays a critical role in the pathogenesis of inflammation and recent
reports also implicated it with the pathobiology of atherosclerosis
[2,3,4]. The endocannabinoid system comprises two membrane
receptors, CB1 and CB2, their endogenous ligands, such as
anandamide (arachidonoylethanolamide, AEA) and 2-arachido-
noylglyceral (2-AG), and several enzymes required for their
biosynthesis and inactivation [5,6]. The receptor CB1 is primarily
expressed in the central nervous systems (CNS), but also in
peripheral tissues and on immune cells [7]. Selective blockade of
the CB1 receptor inhibits atherogenesis in LDL receptor (LDLR)-
deficient mice [8].
The CB2 receptor is predominantly expressed in immune and
hematopoetic cells but also in adipose tissue [9], brain [10],
myocardium [11], and endothelial cells [12]. Numerous studies
have demonstrated anti-inflammatory effects of CB2 receptor
activation in different diseases and pathological conditions,
including cerebral injury [13,14], inflammatory pain [15], and
myocardial injury [16]. Most notably, CB2 receptor activation has
also been suggested to modulate atherosclerosis [17]. In this latter
study, Steffens and colleagues showed that oral administration of
low doses of D
9-tetrahydrocannabinol (THC, 1 mg/kg per day)
significantly reduced plaque progression in apolipoprotein E
(ApoE) knockout mice. They also observed CB2 receptor-
expressing immune cells in Murine and human atherosclerotic
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of THC-treated mice. Since these effects were reversed by a
selective CB2 but not CB1 receptor antagonist, the authors
hypothesized the involvement of CB2 receptors on immune cells
in atherogenesis [17]. Another recent study also showed ameliora-
tion of atherosclerosis in ApoE-deficient mice after treatment with a
CB2/CB1 receptor agonist and the authors postulated a CB2
receptor-dependent effect [3]. However, up to now no in vivo study
evaluated the direct contribution of CB2 receptor signaling in the
context of atherosclerosis. There is a need for such studies to
ultimately evaluate whether CB2-targeted therapies may be suitable
to fight atherosclerosis. Therefore, the aim of this study was to
investigate the influenceof the CB2 receptor on atherogenesis inlow
density lipoprotein receptor (LDLR)-deficient mice.
Methods
In vivo study
CB2-deficient mice and LDLR-deficient mice, both on a pure
C57/BL6 background, were obtained from Jackson Laboratories.
Mice were crossbred to generate CB2
2/2/LDLR
2/2 mice.
Genotyping of each mouse used polymerase chain reaction and
employed the following primers: LDLR, 59-CCA TAT gCA TCC
CCA gTC TT-39 (common primer), 59-gCg ATg gAT ACA CTC
ACT gC-39 (wild-type primer), 59-AAT CCA TCT TgT TCA
ATg gCC gAT C-39 (mutant primer); CB2,5 9- gAC Tag AgC
TTT gTA ggT Agg Cgg -39 (common primer), 59- ggA gTT CAA
CCC CAT gAA ggA gTA-39 (wild-type primer) and CB2,5 9- ggg
gAT CgA TCC gTC CTg TAA gTC T-39 (mutant primer). Six-
week-old male CB2
+/+/LDLR
2/2 and CB2
2/2/LDLR
2/2 mice
consumed a high-cholesterol diet (HCD) for 16 weeks (Ssniff
modified after Research Diets D12108 containing 21% total fat
and 1.235% cholesterol, Soest, Germany). In parallel, JWH-133
(diluted in a water-soluble solution with Tocrisolve, from Tocris,
Bristol, UK) or vehicle was injected intra-peritoneally (i.p.) into
LDLR-deficient mice consuming HCD at a concentration of
5 mg/kg body weight three times a week for 16 weeks.
Subsequently, mice were euthanized, hearts and aortas were
removed, and tissue was prepared and analyzed histologically as
described previously [18,19,20]. Total cholesterol and triglyceride
levels were assayed in EDTA plasma from blood obtained by
retro-orbital bleeding before feeding and drawn from the right
ventricle upon harvest. The total wall area (=intima + media),
intimal lesion area (intima) and medial area (media) as well as the
percentage of positively stained area for macrophages (anti-mouse
Mac-3), lipids (Oil-Red-O), T cells (anti-CD4), collagen (Picrosir-
ius red), smooth muscle cells (anti-a-actin), and apoptotic cells
(TUNEL, Roche, Basel, Switzerland) were quantified by blinded
investigators employing computer-assisted image analysis software
(Image Pro, Media Cybernetics, Bethesda, MD). Abdominal
aortas were fixed with 10% formalin, opened longitudinally,
pinned, stained with Oil-red-O solution (Sigma-Aldrich, St. Louis,
MO, 2.5 h, RT), washed with 85% propylene glycol, and lipid
accumulation was quantified as described above. All mice were
housed under specific pathogen-free conditions. All procedures
were approved by the Animal Care Committee of the University
of Freiburg and the local authorities (Regierungspra ¨sidium
Freiburg) with the permit number G-08/46.
Cell Culture and in vitro stimulation
Murine endothelial cells were isolated using Invitrogen
DynabeadsH (Invitrogen, Paisley, UK) as previously described
[21]. Endothelial cells were seeded in 6 or 24 wells until they
reached 80% confluence. Flow cytometric analysis for PECAM-1
and ICAM-2 showed a purity of about 97% of isolated murine
endothelial cells (data not shown). After incubation in FCS-free
medium for 24 hours, cells were stimulated with indicated
concentrations of JWH-133 or vehicle, followed by TNFa
(20 ng/ml) after 30 minutes. After 24 hours of incubation at
37uC supernatents were removed for ELISA and endothelial cells
were lysed and used for Western Blotting. Apoptosis and
cytotoxicity was evaluated by Apo-ONEH and CytoTox-One
TM
Assay according to the instructions of the manufacturer (Promega,
Madison, WI).
Enzyme-linked immuno-absorbent assay (ELISA)
Mouse MCP-1 was quantified in the supernatants of cell
cultures using commercially available ELISA Kits (R&D DuoSet,
Minneapolis, MN) according to the manufacturer’s instructions.
Western blotting
Murine endothelial cells were stimulated with TNFa (20 ng/ml)
for 24 hours. After incubation, murine endothelial cells were lysed,
separated by SDS-PAGE under reducing conditions, and blotted
to polyvinylidene difluoride membranes as described previously
[21]. An anti-mouse ICAM-1 antibody (Santa Cruz, Santa Cruz,
CA) was used as primary antibody, followed by an anti-
peroxidase-conjugated AffiniPure Goat Anti-Rabbit IgG (Jackson
Laboratories, West Grove, PA) as secondary antibody.
Cytokine challenge and cytometric bead assay
To induce inflammation, mice were subjected to intraperitoneal
injection of TNFa (200 ng/ml) as indicated. Blood was collected by
cardiacpunctureandserumseparation.Foranalysisofinflammatory
markers in mice the cytometric bead assay for Murine inflammation
detecting IL-6, MCP-1, IFNc, IL-10, and IL-12p70 was used
according to manufacturer’s instructions (BD Biosciences, San
Diego, CA) optimized for higher sensitivity. Results were analyzed
using the corresponding FCAP software (BD Franklin Lakes, NJ).
The lower detection limits were in the range of 5–10 pg/ml.
Dynamic adhesion assays
Dynamic adhesion assays in the flow chamber were performed
as described previously [19]. Murine endothelial cells were grown
in 35 mm dishes (Costar, Bethesda, MD) and were subjected to the
flow chamber. In brief, the Glycotech flow chamber (Gaithers-
burg, MD) was assembled with the dish as the bottom of the
resulting parallel flow chamber. The chamber and tubes were
filled with PBS without serum prior to the experiment.
Subsequently, Murine leukocytes were applied with a syringe
pump (Harvard apparatus PHD2000, Holliston, MA) with flow
rates of 0.04 dyne/cm
2 (venous flow; a total of 10 min). Adherent
cells were quantified under the microscope.
Flow cytometry
Flow cytometry was performed as previously described [22].
Cells were pre-incubated with mouse Fc-Block (aCD16/32,
ebioscience, San Diego, CA). Antibodies included CD11b-FITC,
CD115-PE, Ly6C/G (Gr1)-APC, CD4-Alexa488, CD8-PE, CD3-
APC, CD20-PE, ICAM-1-FITC (all from ebioscience, San Diego,
CA), ICAM-2-FITC, and PECAM-1-PE (PharMingen, San
Diego, CA). The mean fluorescence indices (MFI) were quantified
employing the FlowJo software (Tree Star Inc, Ashland, OR).
Murine peritonitis
CB2
+/+/LDLR
2/2 and CB2
2/2/LDLR
2/2 mice were treated
intraperitoneally with 4% thioglycollate. After 4 and 72 hours,
CB2 and Atherosclerosis
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with 6 ml of RPMI for 3 min. Leukocytes were quantified in a
CASY counter. Similarly, wild-type (Bl6) mice received JWH-133
one hour before injection of 4% thioglycollate. The resulting
leukocyte migration was measured after 4 and 72 hours.
Mass spectrometry - pharmacokinetics of JWH-133
Mice were subjected to i.p. injection of JWH-133 (5 mg/kg
body weight) on day 1, 3, 6, 8 and 10. On day 10 retro-orbital
blood was taken at 2, 12, 24, and 48 hours after the last injection
of JHW-133. Mouse sera (100 ml, N=6) were added to 5 ml
internal standard (d3-THC; 5 mg/ml in ethanol), followed by
2.9 ml acetic acid 0.1 M, followed by automated solid phase
extraction using Aspec GX-274 (Gilson, Middleton, USA),
reversed phase C18 SPE-cartouche (type chromabond), and a
500 mg column bed (Macherey-Nagel, Du ¨ren, Germany). Sam-
ples were eluted with 1 ml acetonitrile, evaporated in a stream of
nitrogen at 40uC, and incorporated in 25 ml ethyl acetate.
Frozen aortic tissue was incubated in 500 ml ethanol in an
ultrasound bath twice for 15 min, pooled, 25 ng internal standard
was added (d3-THC), samples were evaporated in a stream of
nitrogen at 40uC, reconstituted in ethanol, acetic acid was added,
and automated solid phase extraction and elutriation was
performed as described above.
1 ml of samples was analyzed using the Agilent 5973 GC-MS
system (temperature gradient 100uC for 1 min, increase to 290uC
for 2.5 min, increase to 310uC for 4 min, fragmentation energy
70 eV). The following fragments were chosen. For JWH-133: m/z
269 (quantifier), m/z 312 and m/z 229 (qualifier), retention time
6.5 min. For d3-THC: m/z 302 (quantifier), m/z 317 and m/z
234 (qualifier), retention time 7.4 min. The detection limit was
25 ng/ml.
Quantitative real-time PCR. Aortas from CB2
2/2/
LDLR
2/2 and CB2
+/+/LDLR
2/2 mice consuming HCD for
16 weeks were harvested and stored in RNAlater (Qiagen, Venlo,
Netherlands) at 280uC. Total RNA was extracted using TRIzol
Reagent (Invitrogen, San Diego, CA) and glycogen as a co-
precipitator (Roche, Basel, Switzerland). Homogenization was
performed using a rotor-stator dispergator (IKAH, Staufen,
Germany). 1 mg of total RNA was transcribed into cDNA using
the Transcriptor First Strand cDNA Synthesis Kit (Roche, Basel,
Switzerland). Subsequent quantitative real-time PCR was
performed with a LightCycler 480 System using the LightCycler
480 SYBR Green I Master (Roche) detection format. mGAP-DH
served as endogenous control. Primer sequences: mCNR1: 59-
TCC TTG TAG CAG AGA GCC AGC C-39 (forward), 59-GCC
AGG CTC AAC GTG ACT GAG A-39 (reverse); mGAP-DH: 59-
TGC ACC ACC AAC TGC TTA G-39 (forward), 59-GAT GCA
GGG ATG ATG TTC-39 (reverse).
Statistical analysis
Data are expressed as means 6 SEM of absolute or normalized
values. Groups were compared employing the Student’s t-test. A
value of P,0.05 was considered significant. Data sets were
analysed using GraphPad PrismH (GraphPad Software Inc, La
Jolla, CA).
Results
Treatment with the selective CB2 receptor agonist JWH-
133 does not attenuate atherogenesis in mice
To explore the contribution of direct CB2 receptor stimulation
LDLR
2/2 mice consuming a high-cholesterol diet (HCD) for 16
weeks were treated with intraperitoneal injections of the selective
CB2 receptor agonist JWH-133 or vehicle three times a week.
JWH-133 was detectable in mouse serum after 2, 12, and 24 hours
by mass spectrometry, proving bioavailability in vivo (Fig. 1). More
importantly, JWH-133 could also be detected directly in aortic
tissue of treated animals 48 hours after administration at a level of
2.260.67 ng/mg while it was undetectable in vehicle control-
treated animals. Weights, cholesterol levels, and total leukocyte
numbers did not differ between the study groups at baseline and
end of feeding. Both groups also showed no difference in visceral
fat mass, blood pressure, heart rate, and leukocyte subtypes as
quantified at the end of the study (Table 1). Surprisingly, intimal
lesion size in aortic roots was similar between JWH-133-treated
mice and those receiving vehicle control (0.31660.038 mm
2,
N=10 vs. 0.31260.044 mm
2, N=8, P=0.94; Fig. 2A). Similar
results were obtained in aortic arches (0.09160.024 mm
2,N=1 1
vs. 0.06660.013 mm
2, N=8, P=0.41, Fig. 2B). Also, lipid
deposition in en face analysis of abdominal aortas did not differ
between both groups (Fig. 2C), demonstrating that CB2 receptor
stimulation does not attenuate atherogenesis in mice. Similarly,
JWH-133 treatment did not modulate the content of lipids,
macrophages, collagen, T cells, smooth muscle cells, and the
cellular apoptosis rates in atherosclerotic plaques (Fig. 2D).
CB2 receptor deficiency does not affect the development
of atherosclerotic lesions in mice
Consistent with our results for selective CB2 receptor stimula-
tion, CB2
2/2/LDLR
2/2 mice consuming HCD for 16 weeks
developed lesions of similar size as respective CB2
+/+/LDLR
2/2
control animals in aortic roots (0.26160.038 mm
2, N=12 vs.
0.22360.023 mm
2, N=13, P=0.40, Figure 3A), aortic arches
(0.09560.022 mm
2, N=12 vs. 0.07560.022 mm
2, N=13,
P=0.54, Figure 3B), and abdominal aortas (Fig. 3C). Again,
there was no change in the degree of apoptosis, the content of
collagen, T cells, and smooth muscle cells within the atheroscle-
rotic plaque. However, we could detect increased lipid and
macrophage content (Fig. 3D). CB1 expression quantified by RT-
PCR did not differ between both groups rendering a CB1-driven
bias unlikely (0.001360.0002 vs. 0.001860.0004, P=0.34, N=3).
Figure 1. Pharmacokinetics of JWH-133 using mass spectrom-
etry. Mice were subjected to intraperitoneal injection of JWH-133
(5 mg/kg body weight) on day 1, 3, 6, 8, and 10. On day ten, the serum
levels of JWH-133 were determined at the indicated time points using
mass spectrometry. The concentration of JWH-133 is given as the
mean 6 SEM (N=6).
doi:10.1371/journal.pone.0019405.g001
CB2 and Atherosclerosis
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2/2 mice consuming high
cholesterol diet for 16 weeks (HCD) received intraperitoneal injections of 5 mg/kg JWH-133 (N=10) or vehicle control (Tocris, N=8) three times a
week. Intimal lesion area in the aortic root (A) and arch (B) are diplayed as pooled data 6 SEM; representative images stained for lipid deposition (Oil-
red-O) are shown below the corresponding graph. C, The abdominal aortas of mice treated as described above underwent en face analysis of lipid
deposition. Oil-red-O-positive staining in relation to total wall area was quantified and is displayed as pooled data 6 SEM (N=8 and 10);
representative images are shown below. D, Sections of aortic roots of mice treated as described above were analyzed for lipid-, macrophage-,
collagen-, T cell-, smooth muscle cell- and apoptotic cell content. Oil-red-O-, Mac-3-, picosirius red-, CD4-, a-actin- and TUNEL-positive staining in
relation to total wall area is given as mean 6 SEM (N=8 and 10).
doi:10.1371/journal.pone.0019405.g002
Table 1. Characteristics of study animals before and after feeding.
Tocris
(N=12)
JWH-133
(N=17) p-value
CB2
+/+/LDLR
2/2
(N=17)
CB2
2/2/LDLR
2/2
(N=18) p-value
Weight (g) BF 20.9560.91 19.1760.74 0.14 21.8560.45 22.3660.42 0.42
AF 31.2861.27 30.8960.93 0.80 33.0361.07 35.5761.12 0.11
Cholesterol (mg/dl) BF 191.5611.82 201.0611.82 0.59 194.7611.47 183.267.66 0.41
AF 907.66120.9 1064.06195.7 0.54 777.0648.55 852.06108.3 0.54
Triglycerides (mg/dl) BF 98.84611.67 146.0615.78 0.04 163.9621.29 137.169.23 0.26
AF 255.8650.95 219.2623.13 0.48 194.5621.81 202.7621.36 0.79
Visceral fat pads (g) AF 1.260.21 1.0160.16 0.68 1.3160.17 1.5360.20 0.41
Systolic Blood Pressure (mmHg) AF 102.863.77 107.166.04 0.57 98.9662.49 104.263.86 0.27
Heart rate (bpm) AF 679.8617.78 634.6617.01 0.08 615.2616.16 659.1618.79 0.09
Leukocytes (61000/ml) BF 10.7360.79 10.7160.85 0.98 9.7760.57 10.9360.55 0.15
AF 4.561.02 6.4960.72 0.11 6.9260.89 6.3660.55 0.59
CD3+ (% leukocytes) AF 26.4563.46 21.7362.71 0.29 19.4762.40 20.1361.85 0.83
CD4+ (% leukocytes) AF 12.5561.71 9.460.66 0.07 8.4760.87 9.7560.78 0.28
CD8+ (% leukocytes) AF 9.3661.05 7.5360.58 0.12 7.1360.62 7.6860.59 0.52
CD20+ (% leukocytes) AF 12.2762.27 19.1363.52 0.15 12.061.85 19.1964.71 0.18
doi:10.1371/journal.pone.0019405.t001
CB2 and Atherosclerosis
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and end of feeding (Table 1).
CB2 receptor signaling differentially affects inflammatory
cell recruitment
Since previous reports implicated the CB2 receptor in the
recruitment of inflammatory cells, we investigated a potential role
of CB2 receptor signaling in Murine peritonitis [12,23,24].
72 hours after intraperitoneal injection of thioglycollate peritoneal
macrophage numbers were significantly reduced in JWH-133-
treated mice compared with vehicle controls (Fig. 4A N=5 per
group). In contrast, JWH-133 treatment did not affect short term
(4 h) thioglycollate-induced peritonitis predominated by neutro-
phils (Fig. 4A, N=9 per group). Similar amounts of leukocytes
accumulated in the peritoneal cavity of CB2
2/2/LDLR
2/2 mice
and CB2
+/+/LDLR
2/2 control animals after 72 and 4 hours
(N=5 and N=13 per group, respectively, Fig. 4B). In accord, CB2
receptor signaling did not affect adhesion of inflammatory cells in
the flow chamber (Fig. 4C), expression of ICAM-1 as assessed by
Western blotting (Fig. 5A) and FACS (Fig. 5B), as well as
chemokine expression in cultured endothelial cells (Fig. 5 C).
JWH-133 did not modulate apoptosis (Fig. 5D) and cytotoxicity of
the cells tested (Fig. 5E).
Treatment with JWH-133 attenuates the recruitment of
inflammatory monocytes to the blood pool in an acute
Murine model of inflammation
Since we did not observe an effect of CB2 receptor signaling on
atherosclerosis, a chronic inflammatory disease, we sought to
explore its role in an acute model of inflammation. Interestingly,
neither genetic deficiency nor selective stimulation of CB2 by
JWH-133 modulated the expression of IL-6, MCP-1, IL-10, IFNc,
or IL-12p70 in mice challenged intraperitoneally with TNFa
(Fig. 6A). However, JWH-133-treated mice recruited lower
numbers of monocytes with an inflammatory, GR1
high subtype
to the blood pool upon stimulation with TNFa. Of note, no
difference in numbers of this cellular subtype could be measured
between CB2
2/2/LDLR
2/2 and CB2
+/+/LDLR
2/2 mice.
Discussion
The present study made the surprising finding that selective CB2
receptor stimulation did not affect the development of atheroscle-
rotic plaques in LDLR-deficient mice. Accordingly, deletion of the
CB2 receptor in LDLR-deficient mice did neither increase nor
decrease atheroscleroticburden. Therewas a significantelevation of
lipid and macrophage content in plaques of CB2
2/2/LDLR
2/2
Figure 3. CB2 receptor deficiency does not influence atherosclerosis in mice. A and B, CB2
+/+/LDLR
2/2 (N=13) and CB2
2/2/LDLR
2/2
(N=12) mice consumed HCD for 16 weeks and underwent analysis of intimal lesion area in the aortic root (A) and arch (B). Pooled data 6 SEM are
shown on the left; representative images stained for lipid deposition (Oil-red-O) are displayed below the corresponding graph. C, The abdominal
aortas of mice treated as described above underwent en face analysis of the lipid deposition. Oil-red-O-positive staining in relation to total wall area
was quantified and is dispayed as pooled data 6 SEM (N=13 and 12); representative images are shown below. D, Sections of aortic roots of mice
treated as described above were analyzed for lipid-, macrophage-, collagen-, T cell-, smooth muscle cell- and apoptotic cell content. Oil-red-O-, Mac-
3-, picosirius red-, CD4-, a-actin- and TUNEL-positive staining in relation to total wall area is described as mean 6 SEM (N=13 and 12). Asterisks
indicate a significant change, defined as p,0,05.
doi:10.1371/journal.pone.0019405.g003
CB2 and Atherosclerosis
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atherosclerotic lesion area between CB2
+/+/LDLR
2/2 and CB2
2/2/
LDLR
2/2 mice after 8 or 12 weeks on atherogenic diet. In
accordance with our findings, plaques of these CB2-deficient
animals contained more macrophages [25]. One possible explana-
tion is that CB2 receptor deficiency reduces the susceptibility of
macrophages to oxidzed LDL-induced apoptosis in vitro [26].
Therefore, the elevated macrophage levels in plaques of CB2
2/2/
LDLR
2/2 mice might be the result of reduced apoptosis. Indeed,
Netherland et al. observed decreased cellular apoptosis rates in
atherosclerotic plaques from CB2
2/2/LDLR
2/2 mice [25]. In
contrast, we could not detect CB2-dependent changes in apoptosis
Figure 4. Inflammatory cell recruitment is differentially affected by CB2 receptor stimulation. A, Wild-type mice received intraperitoneal
injections of 4% thioglycollate after pre-treatment with JWH-133 or vehicle control. Leukocyte recruitment into the peritoneal cavity was quantified
after 72 and 4 h. Data represent mean 6 SEM. Asterisks indicate significant change, defined as p,0,05. B, In parallel, thioglycollate-elicited
accumulation of leukocytes in the peritoneal cavity was quantified in CB2
2/2/LDLR
2/2 mice and CB2
+/+/LDLR
2/2 control animals. Data for both 72
and 4 h stimulation are expressed as mean 6 SEM. C, PMA-activated thioglycollate-elicited peritoneal leukocytes obtained from wild-type (Bl6) mice
were allowed to adhere on TNFa-activated endothelial cells (EC) isolated by magnetic bead separation from wild-type mice in the presence or
absence of 40 mM JWH-133. Adhering leukocytes were quantified under microscope after the indicated time points in the flow chamber (N=3 each).
In parallel experiments PMA-activated thioglycollate-elicited peritoneal leukocytes from CB2
2/2/LDLR
2/2 mice were allowed to adhere on TNFa-
activated EC isolated from CB2
2/2/LDLR
2/2 mice. Adhesion was quantified and compared with the interaction of peritoneal leukocytes and EC
isolated from CB2
+/+/LDLR
2/2 (N=5 each). Pooled data represent mean 6 SEM.
doi:10.1371/journal.pone.0019405.g004
CB2 and Atherosclerosis
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associated with more unstable plaques in humans. However, plaque
stability also depends on collagen and smooth muscle content,
which were both not modulated in our study. Furthermore, if CB2
deficiency results in more plaque inflammation and less stability,
one would expect that CB2 agonism promotes less inflamed, more
stable lesions. We could not observe such an effect in animals
treated with JWH-133. In accord, i.p. application of the direct CB2
antagonist SR144528 in HCD-consuming ApoE
2/2 mice did not
modulate atherogenesis in another report [27]. Thus, while we
cannot rule out that CB2 signaling may affect macrophage biology,
in the context of atherosclerosis this does not appear to be relevant.
Since CB1 receptor signaling is thought to be proatherogenic
[8,28,29], we also quantified CB1 mRNA expression via RT-PCR,
showing no significant difference between the CB2
2/2/LDLR
2/2
and CB2
2/2/LDLR
+/+ mice. This makes a CB1-driven bias
unlikely, however we cannot rule out a change of receptor
activation due to receptor internalization.
Our data challenge two previous reports suggesting CB2-
dependent anti-atherosclerotic properties of endocannabinoids
[3,17]. Both studies observed only indirect evidence for a CB2-
dependent effect and lacked the use of highly selective CB2
agonists or genetic CB2 knock-out animals. They demonstrated
attenuation of atherosclerotic lesion formation by the CB1/CB2
agonists tetrahydrocannabinol (THC) and WIN55212-2, effects
partially reversed by treatment with the CB2 antagonists
SR144528 and AM630. Some reports claim selectivity of
WIN-55,212-2 for the CB2 receptor but the compound also
has a relatively high affinity for the CB1 receptor [30]. In
contrast, JWH-133, used in this study, is a potent and selective
CB2 receptor agonist, with a Ki of 3.4 nM and a 200-fold higher
affinity for CB2 over CB1 receptors [31]. Numerous studies used
JWH-133 in vivo at concentrations ranging from 0.015–15 mg/kg
[14,32,33,34,35]. In the present study, we administered JWH-
133 three times a week by intraperitoneal injection for the
complete duration of high cholesterol diet, e.g. 16 weeks. This
regimen resulted in detectable serum and aortic concentrations
of JWH-133 as assessed by mass spectrometry, demonstrating
bioavailability.
Imbalance in the ratio of the T cell subgroups and
inflammatory monocytes as well as in their effector cytokines
can modulate atherogenesis and plaque composition in mice
[36,37]. Several studies have shown that THC regulates Th1/
Th2 cytokine balance in activated human T cells [7,38,39]. The
expression of IFNc was dose-dependently reduced in splenocytes
after THC stimulation in a report whereas only a modest, non-
significant down-regulation of IL-10 and TGFb was detected,
leading the authors to the conclusion that THC induces a dose-
dependant shift in the Th1/Th2 balance [17]. Cytokine levels
were too low to be quantified in our atherosclerosis model. To
investigate whether deficiency or stimulation of the CB2 receptor
has an influence on cells and cytokines also known to be involved
in atherosclerosis, we chose a cytokine challenge model of acute
Murine inflammation. The present study found no difference in
IL-6, MCP-1, IL-10, IFNc, and IL-12p70 expression after
intraperitoneal TNFa challenge in both JWH-133-pretreated
and CB2
2/2/LDLR
2/2 mice compared with respective controls.
Therefore, in contrast to the non-selective THC, selective CB2
stimulation or deletion of the CB2 receptor has no influence on
the expression of these cytokines in vivo. However, mice treated
with JWH-133 for 10 days recruited lower numbers of
inflammatory Gr1
high monocytes to the blood pool after
intraperitoneal TNFa challenge, suggesting that CB2 stimulation
may indeed have short term anti-inflammatory effects.
The recruitment of inflammatory cells (e.g., monocytes and T
lymphocytes) to the intima is an essential step in the development
and progression of atherosclerosis [40]. Rolling, adhesion, and
trans-endothelial migration of leukocytes are triggered by local
production of chemokines, chemokine receptors, and adhesion
molecules [41]. Several previous in vitro studies have investigated
the role of CB2 receptor activation on baseline or stimulated
inflammatory cell migration, with both increases and decreases of
cell migration reported, depending on the endocannabinoid,
synthetic agonist/antagonist, and cell type used [for review, see
42]. Intraperitoneal injection of HU-210 and WIN-55,212-2
reduced the influx of neutrophils into peritoneal cavity in mice in
one report [43]. However, both substances are considered to be
both CB1 and CB2 agonists [44,45,46]. Using the highly selective
CB2 agonist JWH-133, we detected a significant decrease of
macrophage accumulation in the peritoneum of JWH-133-
treated mice 72 hours after thioglycollate injection, suggesting
anti-inflammatory properties of this drug in vivo at the dosage
employed. In contrast, JWH-133 did not affect peritoneal
neutrophil accumulation 4 hours after thioglycollate exposure.
Accordingly, exposure of isolated LDLR
2/2 endothelial cells to
increasing concentrations of JWH-133 followed by TNFa
stimulation did not mitigate MCP-1 and ICAM-1 expression.
We could also not detect any significant differences in the
expression of MCP-1 in TNFa-stimulated endothelial cells,
isolated from CB2
2/2/LDLR
2/2 mice compared to respective
controls. In contrast, Rajesh et al. found a significant decrease of
MCP-1 and ICAM-1 in TNFa-stimulated human coronary
artery endothelial cells after incubation with JWH-133 [12].
This might be due to cell type specific differences and methodical
differences.
There are several limitations of this study that need to be
considered: 1. Despite detection of JWH-133 in mouse serum and
aortas by mass spectrometry, we cannot rule out that the dose of
JWH-133 applied was insufficient to adequately stimulate the CB2
receptor in vivo. This is, however, unlikely since several other
studies applied doses in a similar range to mice in vivo and observed
biological effects [32,33,34,35,47]. Also, even if the dosage was
insufficient one would still expect the genetic deficient animals to
show an opposite effect which they did not in our study. 2. It is
Figure 5. Viability and ICAM-1 expression on murine endothelial cells is unaffected by CB2 receptor signaling. A, Murine EC isolated
from LDLR
2/2 mice were stimulated with or without TNFa (20 ng/ml) and JWH-133 (4 mM and 40 mM, N=4). In parallel, experiments, EC isolated from
CB2
2/2/LDLR
2/2 mice and CB2
+/+/LDLR
2/2 control animals were stimulated with or without TNFa (20 ng/ml, N=6). Cell lysates were analyzed for
ICAM-1 by Western blotting. Western blots were analyzed densitometrically and adjusted for GAP-DH. Pooled data are given as mean 6 SEM and
representative blots are shown. B, Similarly, Murine EC isolated from wild-type mice where stimulated with indicated concentrations of JWH-133 and
with or without TNFa (20 ng/ml). The cells were then analyzed for ICAM-1 expression using flow cytometric assays. Data is shown as mean 6 SEM
(N=6). Asterisks indicate significant change, defined as p,0,05. C, In supernatants of EC treated as described above MCP-1 was quantified by ELISA.
Data is shown as mean 6 SEM. D and E, Murine EC isolated from wild-type mice were stimulated with indicated concentrations of JWH-133 and then
the rate of apoptosis was determined using the Apo-ONEH Assay (D). Data is shown as the mean 6 SEM (N=5). The supernatant of cells treated in a
similar manner were used to examine cytotoxicity with the CytoTox-ONE
TM Assay (E). Data is shown as the percent of control (N=6).
doi:10.1371/journal.pone.0019405.g005
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stages of atherosclerosis as tested in this study. However, one may
question the biological and therapeutic relevance of such effects if
they do not hold up through the course of atherogenesis. Also,
plaques in the aortic arch are generally regarded to be at an earlier
stage of development whereas those in the aortic root are
considered to be more advanced [18]. Since we did not observe
any modulation of atherosclerosis at both sites a stage-dependent
effect is unlikely.
In summary, the present study made the novel observation that
neither CB2 receptor stimulation nor its genetic deficiency
modulates atherogenesis. Therefore, therapies targeting the CB2
receptor may not be beneficial in reducing atherosclerotic
burden.
Figure 6. CB2 receptor stimulation or CB2 receptor deficiency does not affect inflammatory cytokine expression. A, LDLR
2/2 mice
treated intraperitoneally with 5 mg/kg JWH-133 or vehicle control (Tocris, N=6 each) for 10 days were challenged with 200 ng TNFa for 4 hours.
Subsequently, serum samples were analyzed for IL-6, MCP-1, IL-10, IFNc, and IL-12p70 by cytometric bead array. In parallel, experiments the same
analytes were quantified in CB2
2/2/LDLR
2/2 mice and CB2
+/+/LDLR
2/2 control animals after challenge with 200 ng TNFa for 4 hours (N=5 each).
Data represent mean 6 SEM. B, Blood cells obtained from the animals treated as described above were quantified by FACS analysis for expression of
CD11b, CD115, Gr-1, CD62L, CD18, CD14, and CD41. Data represent mean fluorescent intensity or per cent of leukocytes 6 SEM where appropriate.
Asterisks indicate significant change, defined as p,0,05.
doi:10.1371/journal.pone.0019405.g006
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